Table 2.
Cox proportional hazards regression model for the prediction of overall survival.
| Factor | Unit | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | p Value | Hazard Ratio (95% CI) | p Value | |||
| Age | Years Old | ≥70/<70 | 0.96 (0.39–2.39) | 0.939 | ||
| Gender | Male/Female | 0.56 (0.23–1.39) | 0.212 | |||
| ECOG PS | 0/1 | 0.59 (0.17–2.00) | 0.398 | |||
| Etiology | Viral/non-Viral | 1.41 (0.55–3.65) | 0.477 | |||
| PT | % | ≥90/<90 | 1.12 (0.43–2.90) | 0.817 | ||
| ALB | g/dL | ≥4.0/<4.0 | 0.95 (0.35–2.60) | 0.920 | ||
| T-BIL | mg/dL | ≥0.7/<0.7 | 2.26 (0.83–6.18) | 0.112 | ||
| ALBI score | ≥−2.27/<−2.27 | 1.30 (0.55–3.09) | 0.546 | |||
| ALT | U/L | ≥45/<45 | 0.62 (0.14–2.66) | 0.520 | ||
| PLT | ×104/μL | ≥15/<15 | 0.47 (0.16–1.39) | 0.170 | ||
| NLR | ≥3.0/<3.0 | 3.98 (1.62–9.78) | 0.003 | 2.42 (0.80–7.36) | 0.119 | |
| AFP | ng/mL | ≥400/<400 | 4.79 (1.99–11.54) | 0.001 | 4.90 (1.58–15.13) | 0.006 |
| DCP | mAU/mL | ≥200/<200 | 2.96 (1.06–8.25) | 0.038 | 1.72 (0.53–5.57) | 0.365 |
| Prior systemic therapy | Yes/No | 0.99 (0.42–2.34) | 0.984 | |||
| Extrahepatic metastasis | Yes/No | 0.99 (0.42–2.35) | 0.980 | |||
| Macrovascular invasion | Yes/No | 3.61 (1.49–8.76) | 0.005 | 1.85 (0.62–5.59) | 0.273 | |
| Intrahepatic tumor number | ≥5/≤4 | 2.29 (0.96–5.46) | 0.061 | |||
| BCLC stage | A,B/C | 0.46 (0.18–1.18) | 0.104 | |||
| cfDNA | ng/uL | ≥2.23/<2.23 | 2.99 (1.16–7.75) | 0.024 | 2.92 (0.98–8.71) | 0.054 |
| TERT | Yes/No | 3.93 (1.63–9.44) | 0.002 | 3.25 (1.14–9.28) | 0.028 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PT, prothrombin time. ALB, albumin; T-Bil, total bilirubin; ALBI, Albumin-Bilirubin; ALT, alanine aminotransferase. PLT, platelet; NLR, neutrophil-lymphocyte ratio; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin. BCLC, Barcelona clinic liver cancer; cfDNA, cell-free DNA; TERT, telomerase reverse transcriptase.